암 백신 시장 규모, 점유율 및 성장 분석 : 백신 유형별, 기술별, 적응증별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Cancer Vaccines Market size was valued at USD 12.0 Billion in 2024 and is poised to grow from USD 13.32 Billion in 2025 to USD 30.7 Billion by 2033, growing at a CAGR of 11.0% during the forecast period (2026-2033).

The global cancer vaccine market has transitioned from a niche sector to a focal point in healthcare, driven by immuno-oncology advancements and rising demand for effective vaccines. Cancer vaccines serve dual purposes: they can prevent oncogenic viruses and therapeutically prime the immune system against tumor-specific antigens, potentially reducing long-term care costs due to their enduring responses. The market has evolved from traditional prophylactic vaccines to novel autologous therapies and cutting-edge neoantigen and mRNA technologies. Technological innovations, including genomic sequencing and scalable mRNA production, are lowering barriers for development, attracting investment from both the private sector and major pharmaceutical companies for late-stage trials. Additionally, alignment with regulatory frameworks creates lucrative opportunities in adjuvant therapies, emergent markets, and strategic partnerships aimed at personalized vaccine solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Vaccines Market Segments Analysis

Global cancer vaccines market is segmented by vaccine type, technology, indication (cancer type), end-user and region. Based on vaccine type, the market is segmented into Preventive (Prophylactic) Cancer Vaccines, Therapeutic Cancer Vaccines and Combined Vaccines. Based on technology, the market is segmented into Recombinant Cancer Vaccines, mRNA & Neoantigen Personalized Vaccines, Viral Vector & DNA Vaccines, Whole-cell & Dendritic Cell Vaccines, Peptide-based Vaccines and Antigen/Adjuvant Cancer Vaccines. Based on indication (cancer type), the market is segmented into Cervical Cancer, Prostate Cancer, Lung Cancer, Melanoma, Breast Cancer, Colorectal Cancer and Others. Based on end-user, the market is segmented into Hospitals & Clinics, Specialty Cancer Treatment Centers, Research Institutes & Academic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Vaccines Market

The Global Cancer Vaccines market is significantly driven by advancements in antigen discovery, delivery systems, and adjuvant formulation, which have enhanced the efficacy and applicability of cancer vaccines across various tumor types. These innovations reduce scientific ambiguity, facilitate smoother translational processes, and elevate the therapeutic value perceived by clinicians and developers. This environment fosters increased investment, collaborative research efforts, and prioritization of cancer vaccine development within research pipelines. Consequently, the accelerated progression of candidates and the diversification of vaccine types contribute to market growth by enriching the overall product landscape and bolstering confidence among stakeholders in the industry.

Restraints in the Global Cancer Vaccines Market

The complexity of navigating stringent regulatory requirements and diverse approval frameworks across various regions poses a significant challenge for the development and market introduction of cancer vaccines. This multifaceted landscape heightens uncertainty and extends development timelines. The obligation to clearly demonstrate clinical benefits, adapt trial designs effectively, and meet distinct safety standards creates substantial evidentiary demands that can discourage smaller developers while hindering the advancement of their portfolios. The fragmentation of regulatory processes also amplifies the resources needed for compliance and strategic planning, subsequently slowing the progression of new vaccine candidates towards approval and restricting their market entry rates.

Market Trends of the Global Cancer Vaccines Market

The Global Cancer Vaccines market is witnessing a significant shift towards personalized neoantigen vaccines, reflecting the broader movement in precision oncology towards individualized treatments that align with unique patient tumor profiles. Developers are increasingly focusing on biomarker-driven patient selection and diagnostics to optimize therapeutic efficacy. Commercial strategies are being tailored to target specific patient populations, with an emphasis on value-based reimbursement models gaining traction among payers. Additionally, manufacturing and supply chain processes are evolving to adopt agile, on-demand workflows, while regulatory pathways and trial designs are being refined to support these personalized approaches, alongside a growing emphasis on real-world evidence to substantiate clinical benefits across a variety of tumor types.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Cancer Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Preventive (Prophylactic) Cancer Vaccines
• Therapeutic Cancer Vaccines
• Combined Vaccines

Global Cancer Vaccines Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Recombinant Cancer Vaccines
• mRNA & Neoantigen Personalized Vaccines
• Viral Vector & DNA Vaccines
• Whole-cell & Dendritic Cell Vaccines
• Peptide-based Vaccines
• Antigen/Adjuvant Cancer Vaccines

Global Cancer Vaccines Market Size by Indication (Cancer Type) & CAGR (2026-2033)

• Market Overview
• Cervical Cancer
• Prostate Cancer
• Lung Cancer
• Melanoma
• Breast Cancer
• Colorectal Cancer
• Others

Global Cancer Vaccines Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Specialty Cancer Treatment Centers
• Research Institutes & Academic Centers
• Others

Global Cancer Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • US
  • Canada
• Europe (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Technology, Indication (Cancer Type), End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OSE Immunotherapeutics SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PDS Biotechnology Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanpower Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Transgene SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations